Since 2011, when the United States Food and Drug Administration (U.S. FDA) approved ipilimumab (Yervoy®) for malignant melanoma, several immune-checkpoint inhibitors have been granted marketing authorisation. Do you know all the indications? MediPaper made an overview of all the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.
What is new in the treatment of gastrointestinal (GI) cancer? Read our gastrointestinal cancer blog and learn more about the latest advancements in the treatment of colorectal (CRC), gastric, pancreatic, hepatocellular (liver), oesophageal, and biliary (cholangio) carcinoma.
November turns purple for pancreatic cancer awareness. Focus is on one of the most difficult-to-treat tumours with the final objective: to double the survival of pancreatic cancer by 2020. What is your risk to develop pancreatic cancer? And how likely are you to get cured of the disease?
The United States Food and Drug Agency (US FDA) require the development of companion diagnostics (CDx). CDx can help to identify patients at risk and guide patient selection. Moreover, it serves as a marker for treatment outcome. Thus enabling physicians to better balance safety with efficacy. The US FDA motivates the development of a CDx in early stages of clinical studies.
Avelumab and durvalumab both are PD-L1 targeted antibodies, similar to atezolizumab (Tecentriq™), which was recently approved by the US FDA. Tremelimumab is a CTLA-4 inhibitor, similar to ipilimumab. It is a drug with a long history and also known as CP-675,206 and ticilimumab. The drug has been extensively investigated with mixed results.
A phase II proof-of-concept (POC) study investigating the safety and tolerability of immune modulator IMM-101 plus gemcitabine vs. single agent gemcitabine in advanced pancreatic ductal adenocarcinoma (PDAC) showed significant improved progression-free survival (PFS) and overall survival (OS) in metastatic patients receiving the combination treatment.